Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Inventory (2016 - 2025)

Historic Inventory for Gsk (GLAXF) over the last 17 years, with Q3 2025 value amounting to $8.3 billion.

  • Gsk's Inventory rose 733.77% to $8.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 billion, marking a year-over-year increase of 733.77%. This contributed to the annual value of $7.2 billion for FY2024, which is 596.62% up from last year.
  • Per Gsk's latest filing, its Inventory stood at $8.3 billion for Q3 2025, which was up 733.77% from $8.1 billion recorded in Q2 2025.
  • Gsk's Inventory's 5-year high stood at $8.8 billion during Q2 2021, with a 5-year trough of $1.3 billion in Q1 2022.
  • In the last 5 years, Gsk's Inventory had a median value of $7.3 billion in 2024 and averaged $7.0 billion.
  • In the last 5 years, Gsk's Inventory crashed by 8456.43% in 2022 and then surged by 39197.34% in 2023.
  • Quarter analysis of 5 years shows Gsk's Inventory stood at $7.8 billion in 2021, then decreased by 22.57% to $6.0 billion in 2022, then increased by 13.05% to $6.8 billion in 2023, then grew by 6.63% to $7.3 billion in 2024, then increased by 13.43% to $8.3 billion in 2025.
  • Its last three reported values are $8.3 billion in Q3 2025, $8.1 billion for Q2 2025, and $7.6 billion during Q1 2025.